ATR and cancer: The first reported ATR-selective small-molecule inhibitor, Schisandrin B (SchB), abrogated ATR kinase activity and therefore, ATR-mediated UV-induced intra-S-phase and G2/M cell cycle checkpoints, sensitising cancer cells to UV radiation.